Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 1057-1063

  Afshar, Mehran ^a   Al alloosh, Fawaz ^a   Pirrie, Sarah ^b   Rowan, Clare ^a   James, Nicholas D ^a,c   Porfiri, Emilio ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Abiraterone; CRPC; Metastatic prostate cancer; Predictive algorithm

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MENINGEAL METASTASIS; OVERALL SURVIVAL; PATIENT RISK; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; AGED; METASTASIS; MIDDLE AGED; ORCHIECTOMY; PATHOLOGY; PROSTATIC NEOPLASMS;

ADULT; AGED; ANDROSTENES; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84922928576     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hsing AW and Chokkalingam AP: Prostate cancer epidemiology. Front Biosci 11: 1388-1413, 2006.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6): 1079-1092, 2012.
3. Omlin A and de Bono JS: Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep 13: 170-8, 2012.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005, 2011.
5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Eng J of Med 368(138): 48, 2013.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J of Med 367: 1187-1197, 2012.
7. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213-223, 2013.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S and Sartor AO: TROPIC Investigators Lancet. 376(9747): 1147-1154, 2010 Oct.
9. Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G and Tortora G: Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenge. Anti-Can Agen in Med Chem 13(6): 872-886, 2013.
10. Smith TJ, Hillner BE. Bending the Cost Curve of Cancer Care. N Engl J Med 364: 2060-2065, 2011.
11. Shariat SF, Karakiewicz PI, Suardi N and Kattan MW: Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14(14): 4400-4407, 2008.
12. Vlaev I, Chater N. Game relativity: how context influences strategic decision making. J Exp Psychol Learn Mem Cogn 32: 131-149, 2006.
13. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT and Kattan MW: Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 20: 82-88, 2002.
14. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL and Wilding G: Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate specific antigen working group. J of Clin Onc 17(11): 3461-3467, 1999.
15. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin M-E, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M and Scher HI: Phase II Multicenter Study of Abiraterone Acetate Plus Prednisolone Therapy in Patients with Docetaxel-Treated Castration-Resistant Prostate Cancer. J of Clin Onc 28(9): 1496-1501, 2010.
16. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO and Scher HI: Biomarkers in the management and treatment of men with metastatic castration resistant prostate cancer. Eur Urol 61(3): 549-559, 2012.
17. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EP, Dawson NA, Levine EG, Blumenstein BA and Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory Metastatic Prostate Cancer. J of Clin Onc 21(7): 1232-1237, 2003.
18. Daneshmand S, Quek ML and Pinski J: Neuroendocrine differentiation in prostate cancer. Cancer Therapy 3: 383-396, 2005.
19. Huang J, Yao JL, di Saint'Agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 66(13): 1399-1406, 2006.
20. Bahl AK, Bertelli G, Lewis PD, Jenkins P, Aziz A, Davies PJ, Persad R, Smith CG, Hurley K and Mason MD: Correlation of elevated alkaline phosphatase (ALP) and survival in metastatic castration resistant prostate cancer (CRPC) treated with docetaxel chemotherapy: Results of SWSW Uro-oncology Group study from three UK centres. J of Clin Oncol 29: 2011 (suppl 7; abst 206)
21. Angelergues A, Maillet D, Flechon A, Ozguroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, De La Motte Rouge T, Delanoy N, Elaidi R-T and Oudard S: Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J of Clin Oncol 32: 2014 (suppl 4; abst 282).